New publication: TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease

Published: 01 March 2023

Lochmüller Lab Members Published as Authors in Nature Communications Study

We are excited to share that the study “TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease”, containing contributions from several lab members, was published in the journal Nature Communications on February 23, 2023. Postdoc members Dr. Kiran Polavarapu and Dr. Emily O’Connor, along with Dr. Hanns Lochmüller, are all authors on the paper.

This international, multi-center study establishes TEFM as a  candidatemitochondrial disease gene. Recessive or biallelic TEFM mutations were identified in seven patients from five unrelated families with a wide range of infantile or childhood-onset neurological and neuromuscular symptoms. A combination of clinical phenotyping and muscle pathology along with in silico protein analysis, and mitochondrial function investigations helped in establishing the causal effect of TEFM in these patients. Findings from patients were further supported by zebrafish studies, including movement and neuromuscular analysis1.

These data suggest the consideration of TEFM in the genetic diagnostic workup of patients that present with neonatal or childhood onset mitochondrial encephalomyopathy with  fatigable muscle weakness, epilepsy and variable degree of intellectual disability, and some of these patients with neuromuscular junction defect can benefit from early therapeutic intervention.

Read the Full Publication

The article is open access, and available to read here: https://pubmed.ncbi.nlm.nih.gov/36823193/.

Reference

  1. Van Haute, L., O'Connor, E., Díaz-Maldonado, H., Munro, B., Polavarapu, K., Hock, D. H., Arunachal, G., Athanasiou-Fragkouli, A., Bardhan, M., Barth, M., Bonneau, D., Brunetti-Pierri, N., Cappuccio, G., Caruana, N. J., Dominik, N., Goel, H., Helman, G., Houlden, H., Lenaers, G., Mention, K., … Horvath, R. (2023). TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease. Nature communications, 14(1), 1009. https://doi.org/10.1038/s41467-023-36277-7. PMID: 36823193

 

Neuromuscular junction and animal models

Read next...

Kelly and Ofosu papers

New Publication: Gene-specific response to muscle specific kinase agonist antibody in the treatment of congenital myasthenic syndromes

Congenital myasthenic syndromes (CMS) are a group of rare inherited neuromuscular disorders. Although many forms of CMS appear similar clinically, the disease can be caused...
Current opening

We are recruiting: Postdoctoral Fellow in Rare Disease Bioinformatics

The Polavarapu research group is recruiting a Postdoctoral Fellow in Rare Disease Bioinformatics. Working within a multidisciplinary and collaborative research environment, the postholder will provide...

Oral Platform Presentation (Undergraduate) Category Winner!

We are thrilled to share that Katerina was the winner of Undergraduate Category for her presentation titled “Novel gene discovery in congenital myasthenic syndromes using optogenetic zebrafish...
haleyozgefinal

Two Research Lab Members Receive CIHR Funding Awards!

We are excited to share that two of our research team members have received competitive funding awards from the Canadian Institutes of Health Research (CIHR)...
Hanns CRC image (1)

Dr. Hanns Lochmüller’s Canada Research Chair Renewed Through 2032

We are pleased to announce that Dr. Hanns Lochmüller’s Tier 1 Canada Research Chair (CRC) in Neuromuscular Genomics and Health has been renewed through the...
kiran scientist

Dr. Kiran Polavarapu Appointed Scientist at the CHEO Research Institute

We are delighted to congratulate Dr. Kiran Polavarapu on his appointment as Scientist at the Children’s Hospital of Eastern Ontario Research Institute (CHEO RI). This...